April 2026: Closing the Throughput-Quality Gap in Antibody Discovery

Antibody discovery is driven by diverse methodologies, from throughput-driven sequence identification to integrated, quality-aware lead generation. Technologies such as antibody library display, single B-cell sequencing, and next-generation sequencing have enabled increasingly efficient identification of antigen-binding sequences. However, translating these candidates into molecules suitable for downstream development remains a multi-step process influenced by expression efficiency, stability, and manufacturability.

Several recent studies suggest a growing emphasis on combining microfluidic screening platforms, high-throughput (HT) discovery and expression strategies, and early-stage developability assessment within discovery workflows. Rather than focusing solely on binding affinity or sequence enrichment, these approaches aim to incorporate additional layers of functional and biophysical evaluation earlier in the process.

1. Microfluidics and Functional Resolution at the Single-Cell Level

Microfluidic technologies have been explored as a means to address the disconnect between genotype identification and functional phenotype characterization. As summarized in a recent review, microfluidic systems based on valves, microwells, and droplets enable controlled manipulation of antibody-secreting cells within miniaturized environments. 

Droplet-based systems, in particular, support: 

• Encapsulation of single B cells or antibody-producing variants

• Retention of secreted antibodies within picoliter-scale compartments

• Coupled measurement of secretion and binding or cell-based activity

• Sorting based on functional outputs rather than surrogate binding signals

These formats allow screening strategies in which functional activity (e.g., receptor engagement or cell-based responses) can be evaluated directly. In some implementations, co-encapsulation of target cells enables context-dependent functional assays within the same microenvironment. 

At the same time, it is important to note that microfluidic platforms can involve complex device design, and are still primarily used in controlled laboratory settings.

2. High-Throughput Screening and Expression as Enabling Infrastructure

High-throughput antibody discovery platforms have expanded through the integration of library display technologies, single-cell sequencing, and automated screening systems. As described in a recent article, these approaches support rapid identification of antibody variable region sequences from large and diverse repertoires. 

Key capabilities include: 

• Construction and screening of large combinatorial antibody libraries

• Integration of next-generation sequencing (NGS) for clone identification

• Use of FACS and microfluidics for enrichment of high-affinity or specific binders

• Automated and array-based screening formats to increase parallelization

Sequence identification is followed by expression and downstream characterization, forming a multi-step pipeline from library to candidate molecule. However, several steps remain comparatively resource-intensive: 

• Gene synthesis and cloning of selected sequences

• Expression and purification of candidate antibodies

• Functional and biophysical validation

Now, these stages require only two weeks of effort, when large numbers of candidates are advanced in parallel with automation.

3. Early Developability Assessment in Screening

Developability considerations are increasingly discussed in the context of early discovery, particularly as a means to reduce downstream risk. Zhang et al. (2023) define developability in terms of the likelihood that an antibody can be manufactured, formulated, and advanced through development with acceptable properties. 

Key developability attributes include: 

• Homogeneity (e.g., absence of aggregation or heterogeneity)

• Stability (thermal and chemical)

• Solubility (including high-concentration behavior)

• Specificity (including nonspecific interactions)

These properties are influenced by antibody structure and are reflected in measurable outputs such as: 

• Expression yield and productivity

• Aggregation propensity and colloidal stability

• Purity and post-translational modification profiles

These attributes are linked to both molecular features and clinical use considerations, highlighting that acceptable developability criteria may vary depending on indication and dosing requirements. These approaches are intended to enable comparison of multiple candidates with similar functional profiles before advancing to more resource-intensive stages.

Integration Across Discovery Workflows

Taken together, there is a move toward more integrated discovery workflows, in which functional screening, sequence identification, expression, and developability assessment are considered in closer succession rather than as fully independent stages.

For example:

• Microfluidic platforms can provide functional information at the single-cell level

• High-throughput sequencing and screening approaches enable broad sampling of candidate diversity

• Developability assessments introduce additional criteria for prioritization

Ongoing work in antibody discovery is likely to continue exploring how best to balance throughput, functional relevance, and developability considerations within practical experimental constraints. Rather than replacing established methods, microfluidic systems, high-throughput workflows, and early developability assessment are being incorporated alongside existing approaches, contributing to improvements in efficiency and candidate selection.